

**GRx+Biosims** is [three days of insights and actionable ideas](#) geared to addressing issues vital to the generic and biosimilar medicines industry. We've put together an ambitious program filled with a range of topics, discussions and views from industry experts. Here's an overview of our educational tracks to assist in creating a customized curriculum to help further your organization's mission and goals.

# EDUCATIONAL TRACKS FOR 2018



## Stay Informed on Sciences and Regulatory Affairs Issues

Our science and regulatory affairs tracks will give you the insights you need to better navigate the regulatory landscape, and increase your understanding of how our industry can better manage the GDUFA II framework. Plus, be a part of in-depth discussions among diverse stakeholders – industry, academia and the FDA. [View Agenda](#)



## Legal Issues Currently Facing Generic and Biosimilars Companies

Be a part of discussions on a wide variety of emerging legal issues, including the biosimilars patent dance, drug pricing, state legislation, legal Issues in GDUFA, FDARA, and FDA competition proposals, as well as the latest issues in IP and Paragraph IV litigation. [View Agenda](#)



## Get Involved and Get Accredited

AAM will also be providing attendees with the opportunity for CEUs and CLE accreditations through our interactive general and breakout sessions. You'll leave the conference with insightful up-to-date information and earn credits for your continuing education needs. [View Agenda](#)



## Breaking Through on Biosimilars

Take a deep dive into the policy and regulatory challenges facing the nascent biosimilars market in the United States. We will discuss the significant role biosimilars have played in increasing patient access to life-altering medicines and ensuring health system viability globally. Additionally, we will highlight the importance of stakeholder education as a crucial market driver for these innovative medicines.

[View Agenda](#)



## Communicating our Industry Story

It has never been more important to communicate the value of generics and potential of biosimilars. For the first time ever, AAM is providing programming for marketing and communications professionals who tell the stories of the people, products and community service that make our industry special. Learn from experts and peers what resources are available to you, and how to craft compelling content to succeed. [View Agenda](#)